Skip to main content

Table 1 Main epidemiological and clinical features of the discovery and validation patient cohorts

From: Genome-wide pathway analysis identifies VEGF pathway association with oral ulceration in systemic lupus erythematosus

Clinical and epidemiological variablesa Discovery cohort Validation cohort P
Genetic background CEU CEU -
Number of individuals (N) 482 425 -
Gender (% females) 443 (91.91%) 398 (93.65%) 0.37
Average age at onset (m ± SD) 33.50 ± 14.09 32.39 ± 13.32 0.22
Malar rash (N +/N -) 185/174 183/175 1.00
Discoid rash (N +/N -) 46/313 49/309 0.74
Photosensitivity (N +/N -) 191/168 173/185 0.20
Oral ulcers (N +/N -) 153/206 172/186 0.15
Arthritis (N +/N -) 275/84 267/91 0.54
Serositis (N +/N -) 110/249 122/236 0.34
Renal disorder (N +/N -) 120/239 108/250 0.38
Neurologic disorder (N +/N -) 25/334 35/293 0.10
Hematologic disorder (N +/N -) 341/18 337/21 0.63
Immunologic disorder (N +/N -) 289/70 292/66 0.77
Antinuclear antibodies (N +/N -) 346/13 347/11 0.84
  1. Abbreviations: CEU Caucasian European, M mean, N sample size, N + sample size of positive individuals for the clinical variable, N - sample size of negative individuals for the clinical variable, P P value, SD standard deviation
  2. aNumber of individuals shown in the table represents the total number of patients that were initially recruited for the present study. Conversely, the sample size of positive/negative individuals for the indicated clinical phenotype represents the final number of SLE patients having data on both genotype and phenotype available for association analysis